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S U M M A R Y
Objectives: To determine the utility of ‘risk assessment’ in selecting Mycobacterium tuberculosis isolates
for rifampin resistance or rpoB genotyping compared to ‘non-selectively’ genotyping all isolates.
Secondly, we examined the association between past treatment and drug resistance.
Methods: From January 2003 to December 2006, demographic, clinical, and laboratory data were
prospectively collected on patients with laboratory-conﬁrmed tuberculosis (TB). On the basis of past
treatment for active TB infection or known exposure to drug-resistant TB, selected sampleswere sent to a
mycobacterial reference laboratory for rpoB genotyping. A multivariable logistic regression model was
developed to examine the association between past treatment and drug resistance, adjusted for other
factors. Sensitivity, speciﬁcity, and negative and positive predictive values of past treatment as a
predictor for drug resistance were determined.
Results: There were 392 patient episodes of culture-proven TB. Thirty-three drug-resistant isolates were
cultured from 30 patients: 29 (87.9%) were isoniazid-resistant, three (9.1%) were multidrug-resistant
(MDR), and one (3.0%) was rifampin mono-resistant. One patient with isoniazid resistance developed
recurrent disease, and two isolates, initially isoniazid-resistant, mutated and became MDR TB. Based on
risk assessment, rpoB genotyping was performed on 19 samples, and two (10.5%) had mutations that
predictedmultiple drug resistance. Although forMDR TB, a past history of treatment predicted two out of
three patients with acquired resistance, adjusted analysis did not demonstrate a signiﬁcant association
between previous treatment of active TB and drug resistance (odds ratio 1.5, 95% conﬁdence interval (CI)
0.4–5.6). The positive predictive value of past treatment as a predictor for drug resistancewas 12.0% (95%
CI 2.6–31.2%).
Conclusion: Although numbers of MDR TB were too small to draw meaningful conclusions, past
treatmentmay be useful in selecting samples for rpoB genotyping. Overall, previous treatment had a low
positive predictive value for drug resistance in an area bordering East London.
 2010 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Since the mid-1980 s the number of notiﬁed UK cases of
tuberculosis (TB) has continued to rise, and control of this disease
remains a national priority.1 Despite this, there has only been a
small increase in isoniazid and multiple drug resistance (MDR)
with the highest rates of drug resistance occurring in and around
London.2 In cases of MDR and isoniazid-resistant TB, early
identiﬁcation is important for three reasons. Firstly, in cases of* Corresponding author. Tel.: +44 0 845 130 4204x3756/6251;
fax: +44 0 20 8970 5784.
E-mail address: Mark.Melzer@bhrhospitals.nhs.uk (M. Melzer).
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doi:10.1016/j.ijid.2010.02.2247MDR TB, delays in initiating appropriate treatment may result in
poor clinical outcomes.3 Secondly, hospital patients with smear-
positive pulmonary MDR TB pose a cross-infection risk, and
respiratory isolation is required until three consecutive sputa are
smear-negative.4 Finally, patients with isoniazid-resistant TB have
a higher risk of developing MDR TB unless they comply fully with
extended therapy.5
In the early 1990 s, the detection of mutations within an 81-bp
region of the rpoB gene, which encodes a DNA-dependent RNA
polymerase, was shown to have a high positive predictive value for
both rifampin-resistant and MDR TB.6 This assay, termed rifampin
resistance or rpoB genotyping, is available to all National Health
Service (NHS) microbiology laboratories via the mycobacteriology
reference unit (MRU) at a cost of £130/sample. Within NHS truststernational Society for Infectious Diseases.
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smear-positive samples for rifampin resistance genotyping,
some send samples dependent upon ‘perceived risk’, and others
rely on automated liquid TB systems to expedite the time from
smear positivity to culture. Newer molecular tests are available
for the detection of mutations within speciﬁc genes (e.g., inhA,
katG, and aphC) that predict resistance to isoniazid when
performed on TB cultures.7 Unfortunately, unlike viruses such as
HIV, nucleic acid extraction limits the usefulness of multiplex
PCR as a tool for simultaneously resistance genotyping all ﬁrst
line anti-TB agents.
For patients outside London, the National Institute for Health
and Clinical Excellence (NICE) advocates rifampin resistance
genotyping based upon ‘risk assessment’, but for patients in
London the guidance suggests that all samples be submitted for
testing.8 NICE states that ‘risk assessment’ should include previous
treatment, exposure to drug-resistant TB, male gender, age 25–44
years, and HIV co-infection. Confusingly, the guidance also states
that risk assessment should be based on high-incidence countries
for TB, not drug resistance, and ‘the geographical distribution of
drug resistance within the UK’, which NICE do not deﬁne. Recently,
the Health Protection Agency (HPA) recommended resistance
genotyping of all smear-positive pulmonary samples from patients
inside London.9
The aims of this study were two-fold; ﬁrstly, to determine the
utility of risk assessment in selecting samples for rpoB genotyping
and, secondly, to examine the relationship between previous
treatment and drug resistance by determining the sensitivity,
speciﬁcity, positive predictive value (PPV), and negative predictive
value (NPV) of a past history of active TB treatment in predicting
drug resistance, adjusted for other factors.
2. Methods
The study was undertaken at King George, Harold Wood and
Oldchurch hospitals in Essex, part of the Barking, Havering and
Redbridge Trust, which serves an ethnically diverse population of
750 000, bordering East London. Rates of TB vary throughout East
London, but overall the area has seen a 15–20% increase in TB cases
since 2002 and, on average, the incidence exceeds 30/100 000
population.
From January 2003 to December 2006, demographic, clinical,
and laboratory data were prospectively collected on all Barking,
Havering and Redbridge Trust patients with microbiologically
conﬁrmed TB. This included age, gender, country of origin, date of
arrival in the UK, site of infection, HIV serostatus (if known),
previous exposure to drug-resistant TB, smear positivity, culture
results, and drug susceptibilities. In addition, a history of previous
treatment for active disease was recorded based upon patient
recall and, where available, documentation of previous treatment.
All patients with culture-proven TB and drug susceptibility
results, including recurrent episodes, were included in this study.
Recurrence was deﬁned as a further episode of culture-proven TB
two months after starting treatment or the emergence of new
resistance. Patients with recurrent episodes were considered to
have had previous treatment. Patients excluded were those on TB
treatment without microbiological conﬁrmation or those with
smear-positive specimens whose cultures failed to grow, grew
mycobacteria other than TB (MOTT), orwere contaminated. During
the study period, when clinical data were prospectively collected,
and in liaison with the requesting physician, samples were sent for
rifampin genotyping based upon risk assessment, namely if a
patient had a history of previous treatment for active TB infection
or if there was a known exposure to drug-resistant TB. Drug
resistance was deﬁned as MDR, isoniazid, or rifampin resistance.
MDR was deﬁned as resistance to at least rifampin and isoniazid.High-incidence countries for drug resistance were classiﬁed as
sub-Saharan Africa,10,11 the former USSR,11,12 Eastern Europe, and
India.11,13 Based on previous studies and NICE guidance,8 possible
risk factors for drug resistance were considered to be age, gender,
countries with a high incidence of drug resistance, date of arrival in
the UK, HIV serostatus, exposure to drug-resistant TB, and previous
treatment. HIV serostatus was classiﬁed as positive, negative, or
not known. Where date of arrival in the UK was not recorded,
patients were assumed to be UK born.
2.1. Laboratory methods
All samples were auramine stained and subcultured onto
Lowenstein–Jensen and Middlebrook media. All smear-positive
and extrapulmonary samples were directly inoculated into
Kirschner’s broth and the automated liquid MB/BacT system
(Organon, Teknika, Cambridge, UK) to expedite the time to culture.
Speciation was determined by biochemical testing and DNA
hybridization (Accuprobe) and antimicrobial susceptibility per-
formed using the resistance ratio method on Lowenstein–Jensen
medium or the radiometric BACTEC 460 method.14 When
requested, rpoB genotyping was performed at the MRU, London
on smear-positive samples, and results were available within ﬁve
working days. The commercially available assay used was Inno-
Lipa RifTB (Innogenetics, Belgium).
2.2. Treatment protocols
All patients were treated in accordance with British Thoracic
Society guidance.3 For patients with isoniazid resistance, treat-
ment was extended from six to nine months. For MDR TB, an oral
quinolone and injectable aminoglycoside were initially used in
addition to three other susceptible ﬁrst- or second-line anti-
tuberculous drugs. Treatment was extended from six to eighteen
months.
2.3. Statistical analyses
Data were analyzed using STATA 10 (Stata Corp., TX, USA).
Differences in demographic and risk factors for drug-resistant TB
were examined by univariable analysis. The association between
drug resistance and the following variables was determined: age,
gender, high incidence countries for drug resistance, date of arrival
in the UK, HIV serostatus, previous treatment, exposure to drug-
resistant TB, and site of infection. A multivariable logistic
regression model was developed to examine the association
between past treatment and drug resistance, adjusted for those
variables mentioned above. Finally, the sensitivity, speciﬁcity,
NPV, and PPV of past treatment as a predictor for drug resistance
were determined.
3. Results
Over the study period, 632 patients were commenced on TB
treatment and 436 (69.0%) had laboratory evidence of mycobacte-
rial infection (Figure 1). Fifty-six patients were excluded from the
study as their diagnosis was based on histological ﬁndings (n = 23,
41.1%), cultures were contaminated or failed to grow (n = 10,
17.9%), or cultures grew MOTT (n = 23, 41.1%). The MOTT were
Mycobacterium avium (n = 13), Mycobacterium xenopi (n = 7),
Mycobacterium kansasii (n = 2), and Mycobacterium malmoense
(n = 1).
There were 392 episodes of culture-proven TB in the remaining
380 patients. Recurrence occurred at the same site in all patients.
Demographic data and the site of infection in the 380 patients
studied are summarized in Table 1.
Figure 1. Site of infection and smear positivity of culture-positive TB episodes.
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Thirty-three drug-resistant isolates were cultured from 30
patients: 29 (87.9%) were isoniazid-resistant (one patient had
recurrent disease), three (9.1%) were MDR TB, and one (3.0%) was
rifampinmono-resistant. Two isoniazid-resistant isolates mutated
to MDR TB. Nineteen samples, identiﬁed by patient risk assess-
ment, were sent for rpoB genotyping. Five additional samples were
decontaminated with NaOH before a risk assessment was
performed, therefore they were not suitable to send away; repeat
samples were never received. Of the 19 sent for rpoB genotyping,
10 were smear-positive pulmonary samples, one a smear-negative
pulmonary sample, and eight were smear-positive extrapulmon-
ary samples. Two out of 10 (20%) smear-positive pulmonary
samples had rpoB mutations that accurately predicted multiple
drug resistance. One smear-negative pulmonary sample sent for
resistance genotyping was rpoB wild-type. Of the eight smear-
positive extrapulmonary samples, seven were rpoB wild-type and
one assay was unsuccessful.
3.2. Previous treatment
Twenty-four (6.3%) out of 380 patients gave a history of past
treatment for active TB infection. Three (12.5%) of these patientshad resistant isolates, while 21 (87.5%) had sensitive isolates.
Adjusted analysis (Table 2) did not demonstrate a signiﬁcant
association between previous treatment and drug resistance (odds
ratio (OR) 1.5, 95% conﬁdence interval (CI) 0.4–5.6). The sensitivity
of past treatment as a predictor for drug resistance was 9.1% (95%
CI 1.9–24.3), speciﬁcity 93.7% (95% CI 90.6–96.0), NPV 91.6% (95%
CI 88.2–94.3), and PPV 12.0% (95% CI 2.6–31.2%) (Table 3).
4. Discussion
This is the ﬁrst UK study to assess the utility of past treatment in
predicting drug resistance since NICE published TB guidance in
2006.8 We found no association between previous treatment and
overall drug resistance. However, of the three patients with MDR
TB, two initially had isoniazid resistance that mutated to MDR TB.
Bothwere detected by rifampin resistance genotyping, selected for
testing on the basis of perceived risk. Within our Trust, over the
four-year study period, non-selectively genotyping all smear- and
culture-positive samples would have detected one further MDR
case, at a laboratory cost of £48 230.
The strength of this study was the large number of patients
eligible for analysis. Epidemiological, demographic, and microbio-
logical data were collected prospectively and all types of drug
resistance analyzed (e.g., rifampin, isoniazid, andMDRTB). Areas of
Table 1
Demographic data and risk factors for drug resistance in 380 patients with culture-
proven TB
Drug-resistanta
n=30 (7.9%)
Drug-susceptible
n=350 (92.1%)
Age, years
0–19 4 (13.3%) 29 (8.3%)
20–39 18 (60%) 198 (56.6%)
40–59 4 (13.3%) 67 (19.1%)
60–79 4 (13.3%) 38 (10.9%)
80 0 18 (5.1%)
Sex
Male 17 (56.7%) 182 (52%)
Female 13 (43.3%) 168 (48%)
Country of origin
High-incidence (drug resistance) 14 (46.7%) 185 (52.9%)
Low-incidence (drug resistance) 16 (53.3%) 165 (47.1%)
Date of arrival in the UK
<2000 9 (30%) 102 (29.1%)
2000 11 (36.7%) 127 (36.3%)
Missing or UK born 10 (33.3%) 121 (34.6%)
HIV status
Positive 6 (20%) 37 (10.6%)
Negative or not known 24 (80%) 313 (89.4%)
Contact with drug-resistant TB
Yes 1 (3.3%) 1 (0.3%)
No 29 (96.7%) 349 (99.7%)
Site of infection
Pulmonary 20 (66.7%) 196 (56%)
Extrapulmonary 10 (33.3%) 138 (39.4%)
Both 0 16 (4.6%)
Previous treatment
Yes 3 (10%) 21 (6%)
No 27 (90%) 329 (94%)
a Thirty-three drug-resistant isolates were cultured: 29 isoniazid-resistant, three
multidrug-resistant, and one rifampin mono-resistant.
Table 3
The sensitivity, speciﬁcity, positive predictive value, and negative predictive value
of previous treatment as a predictor of drug resistance
Percentage (%) 95% CI
Sensitivity 9.1 1.9–24.3
Speciﬁcity 93.7 90.6–96.0
Positive predictive value 12.0 2.6–31.2
Negative predictive value 91.6 88.2–94.3
CI, conﬁdence interval.
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born’. In determining the utility of past treatment as a predictor of
overall drug resistance, adjustments were made for confounding
factors. A limitation of the study was the small number of patients
with drug-resistant TB, which could have resulted in a signiﬁcant
difference between patients with drug-sensitive and drug-resis-
tant TB being missed. Small numbers of patients with MDR TB also
meant that the sensitivity and speciﬁcity of past treatment for
predicting MDR TB could not be performed. Although the data
were collected prospectively, there was recall bias, as some
patients had difﬁculty remembering previous treatment or
exposure to TB. Cultural differences and fear of stigmatization
may have contributed to failure to disclose all information.15
Nationally, four papers were referenced by NICE in their
guidance on risk assessment for drug resistance. Three studies
were based in London, the other in Leicester. Risk factors for allTable 2
Results of univariable and multivariable logistic regression with drug resistance as out
Univariable regression
OR 95% CI
Previous treatment 1.48 0.42–5.26
Agea - -
Sex
Female 0.80 0.39–1.65
Country of origin
High incidence (drug resistance) 0.73 0.36–1.51
Date of arrival in UK
2000 0.96 0.40–2.30
Missing/not applicable 0.94 0.38–2.31
HIV-positive 1.87 0.73–4.84
Previous exposure to drug-resistant TB 10.87 0.66–178.0
OR, odds ratio; CI, conﬁdence interval.
a Age was divided into quintiles and analysis for trend was performed.types of resistancewere considered. In a retrospective study of 292
patients from the London Chest Hospital in East London, previous
treatment was the most signiﬁcant factor associated with drug
resistance (OR 22.8, 95% CI unknown). Other risk factors were
bilateral disease and young age.16 In the second paper, a
prospective study where 25 217M. tuberculosis isolates were
tested and 1523 (6.1%) were drug-resistant, previous treatment
was a major risk factor, but also young age, male gender, being
foreign born, previous treatment, and HIV serostatus.17 Uniquely,
the third study identiﬁed arrival in the UKwithin the last ﬁve years
as a risk factor in those previously treated for TB.18 Finally, in a
case–control study from Leicester,19 poor adherence to treatment
and previous TB (OR 3.7, 95% CI 1.2–11.8) were identiﬁed as risk
factors for drug resistance. Consistently, in all studies, the odds
ratio for previous treatment was higher than other variables that
were inconsistently associated with drug resistance. Despite this,
NICE failed to prioritize risk factors and equally weighted previous
treatment with being foreign born, residence in London, male
gender, HIV seropositivity, and age between 25 and 44 years.
There are several international studies evaluating the utility of
risk assessment for TB drug resistance. The studies are from
Europe,12,20–23 North America,24–26 South Asia,27–31 the Middle
East,32 and sub-Saharan Africa.33–35 A variety of methods were
used including meta-analysis, cross-sectional surveys, case–
control studies, and prospective cohort studies. Some studies
considered MDR; others considered all types of resistance. Patient
numbers ranged from 250 to 25 000 and most included new
and previously treated patients. One study compared civilian and
prison populations,23 another refugees and non-refugees,35 and
another patients with pulmonary and pleural infections.26 In all
studies, previous treatment was the most signiﬁcant risk factor for
drug resistance. Age, gender, being foreign born, country of origin,
prison, intravenous drug use, HIV serostatus, cavities on chest X-
ray, and sites of infection were cited inconsistently and, compared
to previous treatment, were a less signiﬁcant risk.
Although past treatment is a signiﬁcant risk factor, it is only a
risk factor for acquired resistance and not primary drug resistance.
One UK study attempted to distinguish between risk factors forcome
Multivariable regression
p-Value OR 95% CI p-Value
0.62 1.53 0.41–5.62 0.52
0.40 - - 0.46
0.55 0.70 0.33–1.49 0.36
0.40 0.61 0.25–1.47 0.27
0.92 0.705 0.27–1.87 0.48
0.90 0.54 0.18–1.61 0.27
0.19 1.93 0.70–5.23 0.19
0.09 12.84 0.68–240.2 0.09
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previously treated for TB, smear positivity and arrival in the UK
in the last ﬁve years were strongly associated with isoniazid and
multiple drug resistance. In patients without previous treatment,
residence in London and foreign birthwere risk factors formultiple
drug resistance. For isoniazid resistance, non-white ethnicity,
residence in London, and HIV infection were risk factors.
The predominant risk for primary drug resistance is exposure
to drug-resistant TB. This history is unreliable as few patients
recall or are aware of exposure. A recent London-wide analysis of
the epidemiology and transmission of TB by restriction fragment
length polymorphism (RFLP) typing revealed little evidence of
disease transmission.36 However, in North London, an outbreak
of isoniazid-resistant TB is on-going, with male gender, white or
black Caribbean ethnicity, homelessness, time in prison, and
intravenous drug use being common associations.37 Nosocomi-
ally-acquired MDR TB in cohorts of HIV-infected patients4 has
been documented and, more recently, a ﬁfth of patients with
MDR TB in 2004–2005 were shown to have indistinguishable
strains.2
Our ﬁndings suggest that for MDR TB, compared to overall drug
resistance, a past history of treatment is potentially useful when
deciding which samples to send for rifampin resistance genotyp-
ing, although a larger study is required. By adopting a risk-based
approach, the costs saved by performing fewer tests must be
balanced against the costs of managing an MDR TB outbreak that
may have been averted or limited if results had been available
earlier. In the outbreak amongst HIV-seropositive patients at St
Thomas’ Hospital,4 lasting ﬁve years and resulting in three deaths,
the cost to the trust was in excess of £300 000. However, lessons
learned, including high levels of suspicion, early detection, and
respiratory isolation in negative pressure side rooms, have
signiﬁcantly decreased the risk of future outbreaks in NHS
hospitals.
In the UK, despite the rising prevalence of new cases of TB, the
proportion of drug resistance has remained constant. Risk
assessment proved useful in selecting samples for rpoB genotyping,
as two out of three cases of MDR TBwere detected at an early stage
of infection. Although these data accord with NICE guidance,
namely that non-selectively sending all samples for rpoB
genotyping from patients outside London is unlikely to be cost-
effective, numbers of MDR TB were too small to draw meaningful
conclusions. However, for overall resistance, we found that
previous treatment had a low PPV for drug resistance and
therefore we conclude that a history of past treatment should
not be used as a reliable predictor of drug resistance.
Acknowledgements
We would like to thank Dr Sandra Lacey who helped with the
data collection, and the Barking, Havering and Redbridge NHS
Research and Development group who provided ﬁnancial assis-
tance for the statistical analysis.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. Donaldson L. Stopping tuberculosis in England. An action plan from the Chief
Medical Ofﬁcer. London: Department of Health; October 2004. Available at:
http://www.dh.gov.uk. (accessed on 10/01/2010).
2. Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG.
Increasing antituberculosis drug resistance in the United Kingdom: analysis of
national surveillance data. BMJ 2008;336:1231–4.
3. Anderson C, Moore J, Kruijshaar M, Abubakar I. Tuberculosis in the UK. Annual
report on tuberculosis surveillance in the UK 2008. http://www.hpa.org.uk/
web/HPAwebFile/HPAweb_C/1224268885463. (accessed on 31/5/2010).
4. Breathnach AS, de Ruiter A, Holdsworth GM, Bateman NT, O’Sullivan DG, Rees
PJ. An outbreak of multi-drug-resistant tuberculosis in a London teaching
hospital. J Hosp Infect 1998;39:111–7.5. Ormerod P, Chair of Joint Tuberculosis Committee of British Thoracic Society.
Chemotherapy and management of tuberculosis in the United Kingdom:
recommendations 1998. Thorax 1998;53:536–48.
6. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, ColstonMJ, et al. Detection of
rifampicin-resistant mutations inMycobacterium tuberculosis. Lancet 1993;341:
647–50.
7. Melzer M, Brown TJ, French GL, Dickens A, McHugh TD, Bagg LR. Molecular
analysis of drug resistant TB. Thorax 2002;57:562–3.
8. Tuberculosis: clinical diagnosis andmanagement of tuberculosis, andmeasures
for its prevention and control. London: National Institute for Health and Clinical
Excellence; 2006. Available at: http://www.nice.org.uk/CG033. (accessed on
10/01/2010).
9. Health Protection Agency, 2008. Available at: http://www.hpa.org.uk (accessed
on 10/01/2010).
10. Centers for Disease Control and Prevention (CDC). Emergence ofMycobacterium
tuberculosis with extensive resistance to second-line drugs—worldwide, 2000-
2004. MMWR Morb Mortal Wkly Rep 2006; 55:301–5.
11. Zignol M, Hosseini MS, Wright A, Weezenbeck CL, Nunn P, Watt CJ.
Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:
479–85.
12. Falzon D, Infuso A, Ait-Belghiti F. In the European Union, TB patients from
former Soviet countries have a high risk of multidrug resistance. Int J Tuberc
Lung Dis 2006;10:954–8.
13. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K. Epidemiology
of antituberculosis drug resistance 2002-07: an updated analysis of the Global
Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:
1861–73.
14. Collins CH, Grange JM, Yates MD. Tuberculosis bacteriology: organization and
practice. Oxford, UK: Butterworth-Heinemann; 1997.
15. Lietooghe R, Michiels N, Habib S, Moran MB, Muynck A. Perception and social
consequences of tuberculosis, a focus group study of tuberculosis patients in
Sialkot, Pakistan. Soc Sci Med 1995;41:1685–92.
16. al Jarad N, Parastatides S, Paul EA, Sheldon CD, Gaya H, Rudd RM. Characteristics
of patients with drug resistant and drug sensitive tuberculosis in East London
between 1984 and 1992. Thorax 1994;49:808–10.
17. Djuretic T, Herbert J, Drobniewski F, Yates M, Smith EG, Magee JG. Antibiotic
resistant tuberculosis in the United Kingdom 1993-1999. Thorax 2002;57:477–
82.
18. Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniewski FA, Watson JM. Explain-
ing risk factors for drug-resistant tuberculosis in England and Wales: contri-
bution of primary and secondary drug resistance. Epidemiol Infect 2004;132:
1099–108.
19. Pritchard AJ, Hayward AC, Monk PN, Neal KR. Risk factors for drug resistant
tuberculosis in Leicestershire—poor adherence to treatment remains an im-
portant cause of resistance. Epidemiol Infect 2003;130:481–3.
20. Augustynowicz-Kopec E, Zwolska Z, Jaworski A, Kostrzewa E, Klatt M, Swidersk
A. Frequency of drug resistant tuberculosis in Poland in 2000 as compared to
1997. Pneumonol Alergol Pol 2002;70:193–202.
21. Helbling P, Altpeter E, Raeber PA, Pfyffer GE, Zellweger JP. Surveillance of
antituberculosis drug resistance in Switzerland 1995-1997: the central link.
Eur Respir J 2000;16:200–2.
22. Robert J, Trystram D, Truffot-Pernot C, Carbonnelle B, Grosset J. Surveillance of
Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Myco-
bacteria Study Group. Int J Tuberc Lung Dis 2000;4:665–72.
23. RuddyM, Balabanova Y, Graham C, Fedorin I, Malomanova N, Elisarova E. Rates
of drug resistance and risk factor analysis in civilian and prison patients with
tuberculosis in Samara Region. Russia Thorax 2005;60:130–5.
24. Clark CM, Li J, Driver CR, Munsiff SS. Risk factors for drug-resistant tuberculosis
among non-US born persons in NewYork City. Int J Tuberc Lung Dis 2005;9:964–
9.
25. Moniruzzaman A, Elwood RK, Schulzer M, Fitzgerald JM. Impact of country of
origin on drug-resistant tuberculosis among foreign-born persons in British
Columbia. Int J Tuberc Lung Dis 2006;10:844–50.
26. Baumann MH, Nolan R, Petrini M, Lee YC, Light RW, Schneider E. Pleural
tuberculosis in the United States: incidence and drug resistance. Chest
2007;131:1125–32.
27. Phyu S, Lwin T, Ti T, Maung W, Mar WW, Shein SS. Drug-resistant tuberculosis
in Yangon, Myanmar. Scand J Infect Dis 2005;37:846–51.
28. Dhingra VK, Rajpal S, Bhalla P, Yadav A, Jain SK, Hanif M. Prevalence of initial
drug resistance to M. tuberculosis in new sputum positive RNTCP patients. J
Commun Dis 2003;35:82–9.
29. Paramasivan CN, Venkataraman P, Chandrasekaran V, Bhat S, Narayanan PR.
Surveillance of drug resistance in tuberculosis in two districts of South India. Int
J Tuberc Dis 2002;6:479–84.
30. Santha T, Thomas A, Chandrasekaran V, Selvakumar N, Gopi PG, Subramani R.
Initial drug susceptibility proﬁle of M. tuberculosis among patients under TB
programme in South India. Int J Tuberc Lung Dis 2006;10:52–7.
31. Cox HS, Orozco JD, Male R, Ruesch-Gerdes S, Falzon D, Small I. Multidrug-
resistant tuberculosis in central Asia. Emerg Infect Dis 2004;10:
865–72.
32. Araj GF, Saade M, Itani LY. Nationwide study of drug resistance among acid-fast
bacilli positive pulmonary tuberculosis cases in Lebanon. Int J Tuberc Lung Dis
2006;10:63–7.
33. Wilkinson D, Pillay M, Davies GR, Sturm AW. Resistance to antituberculosis
drugs in rural South Africa: rates, patterns, risks, and transmission dynamics.
Trans R Soc Trop Med Hyg 1996;90:692–5.
M. Melzer et al. / International Journal of Infectious Diseases 14 (2010) e717–e722e72234. Githui WA, Juma ES, Van Gorkom J, Kibuga D, Odhianbo J, Drobniewski F.
Antituberculosis drug resistance surveillance in Kenya, 1995. Int J Tuberc Lung
Dis 1998;2:499–505.
35. Githui WA, Hawken MP, Juma ES, Godfrey-Faussett P, Swai OB, Kibuga DK.
Surveillance of drug-resistant tuberculosis and molecular evaluation of trans-
mission of resistant strains in refugee and non-refugee populations in North-
Eastern Kenya. Int J Tuberc Lung Dis 2000;4:947–55.36. Maguire H, Dale JW, McHugh TD, Butcher PD, Gillespie SH, Costetsos A.
Molecular epidemiology of tuberculosis in London 1995-7 showing low rate
of active transmission. Thorax 2002;57:617–22.
37. Ruddy MC, Davies AP, Yates MD, Yates S, Balasegaram S, Drabu Y. Outbreak
of isoniazid resistant tuberculosis in north London. Thorax 2004;59:
279–85.
